Key takeaways
- There is no single test that measures complete fertility.
- A semen analysis is an important early test.
- AMH estimates egg numbers, not the chance of pregnancy.
- Every test should answer a clear question.
Start with the couple, not an isolated test
A fertility evaluation is designed to answer several different questions: Is ovulation occurring? Are the uterus and fallopian tubes suitable for conception? Is there an adequate number of motile sperm? Are intercourse and ejaculation taking place in a way that allows sperm to reach the reproductive tract? No single blood test or scan answers all of these questions.
Testing both partners in parallel saves time and reduces misplaced blame. Male factors contribute to a substantial proportion of infertility, either alone or together with female factors. Yet some couples complete months of female testing before a semen analysis is requested. A semen analysis is relatively simple and should usually be part of the early work-up. Testing should be selected from history and examination rather than offered as an expensive, identical package to everyone.
History and examination come first
Before ordering tests, the clinician should establish how long the couple has tried, how often intercourse occurs, cycle length, previous pregnancies and losses, past contraception, pelvic or testicular infections, operations, medical conditions and current medicines. Occupational heat or chemical exposure, tobacco, alcohol, anabolic steroids and sexual difficulties may be relevant. A respectful history also includes reproductive goals and the emotional effect of trying to conceive.
Physical examination is personalised. For women it may identify thyroid signs, androgen excess, pelvic tenderness or anatomical concerns. For men it may assess testicular size, varicocele, the reproductive ducts or hormonal features. Examination does not replace laboratory testing, but it helps prevent indiscriminate panels and may identify problems requiring a gynaecologist, reproductive endocrinologist, andrologist or urologist.
Confirming ovulation
Regular cycles between roughly 21 and 35 days often suggest ovulation, but they do not prove it in every case. A mid-luteal progesterone blood test can support evidence of recent ovulation when timed correctly—usually about seven days before the expected next period, not automatically on “day 21.” Urinary luteinising hormone kits identify the hormone surge that commonly precedes ovulation, while ultrasound follicle monitoring can provide more detail when treatment is planned.
Irregular or absent periods may occur with polycystic ovary syndrome, thyroid disorders, high prolactin, major weight change, intensive exercise, perimenopause and other conditions. The appropriate hormonal tests depend on symptoms. Large untargeted hormone panels can produce confusing incidental findings, so results should always be interpreted in relation to cycle timing and clinical history.
Ovarian reserve: AMH and antral follicle count
Anti-Müllerian hormone and the antral follicle count estimate ovarian reserve—the remaining quantity of recruitable follicles. They are particularly useful for anticipating how the ovaries may respond to stimulation and for planning medication doses. A lower AMH may suggest fewer eggs could be retrieved, while a high value may occur in PCOS and can signal a greater risk of excessive response.
These tests do not directly measure egg quality, guarantee natural conception or provide an exact “egg expiry date.” Age remains a stronger predictor of egg chromosomal competence than AMH. A person with low AMH may still ovulate and conceive naturally; someone with high AMH may still face infertility for other reasons. Results should guide counselling, not be used to frighten patients into immediate treatment.
Assessing the uterus and fallopian tubes
Transvaginal ultrasound assesses the uterus, endometrial lining and ovaries. It may identify fibroids, polyps, ovarian cysts, endometriomas or features consistent with PCOS. Some abnormalities are incidental and do not require treatment; their importance depends on size, location, symptoms and whether they affect the uterine cavity.
Tubal patency can be assessed by hysterosalpingography using X-ray contrast, or by ultrasound-based contrast testing where available. These tests can show whether one or both tubes appear open and may outline the uterine cavity. Laparoscopy is not a routine first-line test for every couple because it is invasive, but it may be considered when symptoms or imaging suggest endometriosis, adhesions or other pelvic disease. Hysteroscopy directly examines the uterine cavity when there is a specific indication.
Understanding semen analysis
Semen analysis evaluates volume, sperm concentration, total count, motility and morphology, among other features. Results vary naturally, so one abnormal sample often requires confirmation under appropriate conditions. Collection instructions, the period of abstinence, fever in the preceding months, incomplete collection and transport delays can influence the result. A proper laboratory should follow recognised standards such as the WHO semen manual.
An abnormal result does not automatically mean IVF or ICSI is required. The clinician may investigate hormones, varicocele, obstruction, infection, genetic factors or medication effects depending on severity. Very low counts or absent sperm require timely specialist assessment. Routine sperm DNA fragmentation testing is not necessary for every first evaluation; it may be discussed in selected situations, but its role and effect on management should be made clear.
Tests that are not automatically necessary
More testing is not always better. Immune panels, natural killer cell testing, broad thrombophilia panels, endometrial receptivity tests and extensive genetic panels should not be presented as universal fertility screens. Some have defined indications; others have limited evidence that using them routinely improves the chance of a live birth. Testing should answer a clinical question and lead to an action.
Before agreeing to any test, ask: What are you looking for? How accurate is this test? What will we do differently if it is positive or negative? Is it recommended for someone with my history? What is the total cost? This approach protects patients from expense, anxiety and treatment based on results of uncertain significance.
Turning results into a plan
The final step is synthesis. The clinician should explain whether the findings suggest ovulatory, tubal, uterine, endometriosis-related, male, combined or unexplained infertility. A plan may include timed intercourse, ovulation induction, surgery in selected cases, IUI, IVF, ICSI, donor treatment or fertility preservation. Age, duration of infertility, previous treatment, safety, values and finances all matter.
Ask for copies of every report and a written summary. Parentaura can help you build a question list and compare the logic of proposed next steps, but medical decisions must be made with qualified professionals. Test results are tools for shared decision-making—not verdicts on whether someone can become a parent.
How to interpret “normal” results
A report marked normal does not always mean the probability of conception is optimal, and an abnormal flag does not always establish the cause. Reference ranges describe populations and laboratory methods; they do not combine age, time trying, intercourse, tubal function and embryo biology into one answer. For example, semen values near a lower reference limit may be compatible with conception, while normal semen cannot exclude every sperm-related issue. Similarly, ovulation does not confirm that the tubes are open.
When standard testing is reassuring but pregnancy has not occurred, the term unexplained infertility may be used. It means the routine evaluation has not identified a specific cause; it does not mean the difficulty is imaginary. Treatment choices then depend heavily on age, duration and prior attempts. A younger couple may reasonably try expectant management or limited IUI, while time may justify IVF sooner for an older patient.
Ask the clinician to separate findings into three groups: a likely cause, a contributing factor and an incidental observation. This prevents every fibroid, cyst or borderline laboratory value from being treated. Also ask whether a result needs confirmation and what change would be expected after treatment. Good interpretation reduces both under-treatment and unnecessary intervention.
Suggested Parentaura call to action
Unsure what your results or clinic proposal mean? Parentaura can help you organise your records, prepare questions and understand the choices to discuss with a qualified fertility specialist. We provide independent guidance—not diagnosis, prescriptions or treatment guarantees.
Medical disclaimer
This article is for general educational purposes and is not a substitute for medical advice, diagnosis or treatment. Recommendations vary with age, medical history, examination and local regulation. Consult a qualified clinician who can assess your individual circumstances.